Breaking Ukrainian President Zelenskyy to Visit Serbia Amid Complex Relations with Russia Saudi Arabia, Pakistan, and Turkey Sign Mutual Defense Pact Amid Regional Tensions Westminster Council’s Proposed ‘Vertical Drinking’ Ban Sparks Outcry Senator Murkowski to Oppose Todd Blanche’s Nomination for Attorney General England Forward Ivan Toney Charged With Assault

Friday August 7, 2026

Reporter

Ascletis Pharma Inc.

3Articles Published

5Communities Covered

Published Articles

Press Release

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Aug 3

Press Release

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Jul 27

Press Release

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

Jul 22